Straits Times Index
3,285.82 -1.93 (-0.06%) Nikkei
38,064.16 +435.68 (+1.16%) Hang Seng
17,626.75 +342.21 (+1.98%) FTSE 100
8,078.86 +38.48 (+0.48%) Bitcoin USD
64,155.09 -10.32 (-0.02%) CMC Crypto 200
1,386.66 +4.09 (+0.30%)
Senseonics Holdings, Inc. (SENS)
After hours:
| Previous close | 0.4330 |
| Open | 0.4200 |
| Bid | 0.0000 x 800 |
| Ask | 0.0000 x 2200 |
| Day's range | 0.4016 - 0.4296 |
| 52-week range | 0.3840 - 1.0500 |
| Volume | |
| Avg. volume | 2,579,117 |
| Market cap | 221.988M |
| Beta (5Y monthly) | 0.89 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.1100 |
| Earnings date | 07 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 1.63 |
PR NewswireSAVINGS OFFER FOR THE EVERSENSE E3 CGM EXTENDED TO COVER UNLIMITED NUMBER OF SYSTEMS
Ascensia Diabetes Care, a global diabetes care company and a subsidiary of PHC Holdings Corporation (TSE: 6523), and Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, have announced a significant extension of the Eversense Payment Assistance and Simple Savings (PASS) Program. Designed to help people in the U.S. access the Eversen
Business WireSenseonics Holdings, Inc. Announces Data From the Eversense® Post Approval Study to Be Presented at the 17th International Conference on Advanced Technologies and Treatments for Diabetes
GERMANTOWN, Md., March 08, 2024--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced data from the Eversense® Post Approval Study is to be presented at the 17th International Conference on Advanced Technologies and Treatments for Diabetes ("ATTD") in Florence, Italy.
Business WireSenseonics Holdings, Inc. to Participate in the Oppenheimer 34th Annual Healthcare MedTech and Services Conference
GERMANTOWN, Md., March 06, 2024--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in the upcoming Oppenheimer Healthcare MedTech & Services Conference, being held virtually.
